aminopeptidas
n
wide
express
ectoenzym
function
alway
depend
enzymat
activ
aspect
overlook
numer
tool
develop
last
year
sever
alreadi
undergo
clinic
trial
promis
report
effect
other
anim
model
diseas
howev
efficaci
might
obscur
effect
unrecogn
function
result
unexpect
complic
purpos
review
discuss
variou
function
ascrib
possibl
mechan
behind
ii
consid
question
need
answer
achiev
better
understand
biolog
relev
function
precis
interpret
result
obtain
manipul
ration
design
agent
moonlight
ectoenzym
protein
recogn
multipl
function
term
moonlight
protein
ectoenzym
perfect
exampl
number
function
implic
rapidli
grow
varieti
function
one
member
famili
aminopeptidas
n
apn
also
known
discuss
demonstr
protein
consid
moonlight
ectoenzym
importantli
mani
function
attribut
observ
crosslink
monoclon
antibodi
mab
overexpress
silenc
protein
variou
cell
line
block
enzymat
activ
chemic
inhibitor
anim
recent
describ
therefor
although
vivo
relev
mani
function
yet
determin
interest
therapeut
target
progress
increas
surprisingli
one
aspect
rare
consid
fact
multifunct
protein
thu
ligat
inhibit
enzymat
activ
might
result
complex
system
effect
common
limit
enzym
inhibit
therapi
anticip
drug
lack
knowledg
function
problem
might
exacerb
also
unrecogn
fact
enzymat
activitydepend
independ
function
appear
act
concert
reason
import
review
data
put
establish
function
discuss
possibl
molecular
mechan
involv
investig
aim
toward
clarif
aspect
stimul
shown
figur
perform
known
function
one
follow
mechan
enzymat
cleavag
peptid
also
name
aminopeptidas
n
prefer
neutral
amino
acid
remov
ntermin
amino
acid
unsubstitut
oligopeptid
amid
arylamid
except
peptid
pro
penultim
posit
order
favor
substrat
ala
phe
tyr
leu
arg
thr
trp
ly
ser
asp
val
belong
famili
zinc
metallopeptidas
call
glunzincin
character
presenc
consensu
sequenc
hexxh
glutam
acid
gxmen
motif
third
zincbind
domain
glossari
angiogenesi
process
develop
new
blood
vessel
import
normal
develop
embryo
also
fundament
tumor
growth
chemokin
cytokin
activ
mobil
leukocyt
chemokin
belong
one
four
major
subfamili
ie
c
cc
cxc
subfamili
group
accord
arrang
cystein
residu
receptor
design
chemokin
subfamili
name
follow
letter
r
eg
ectoenzym
enzym
situat
outer
surfac
cell
membran
activ
site
avail
exterior
environ
cell
endocytosi
process
intern
extracellular
materi
liquid
small
solid
particl
variou
intracellular
compart
invagin
cell
membran
fcg
receptor
receptor
immunoglobulin
igg
subtyp
express
leukocyt
respons
effector
function
antibodi
import
modul
immun
respons
glycoform
version
isoform
protein
differ
type
glycan
attach
ie
two
protein
would
glycoform
carri
glycan
differ
glycan
composit
occur
posttransl
cotransl
modif
therefor
amino
acid
sequenc
vari
glycoform
protein
human
coronaviru
speci
genu
coronaviru
one
major
viral
pathogen
caus
upper
respiratori
tract
ill
human
belong
coronaviru
phylogenet
group
inflammatori
bowel
diseas
ibd
group
chronic
intestin
diseas
character
inflamm
larg
small
intestin
common
type
ulcer
coliti
crohn
diseas
isoform
differ
version
protein
correspond
differ
amino
acid
sequenc
origin
differ
gene
loci
multipl
allel
differ
subunit
interact
differ
splice
form
differ
posttransl
modif
phagocytosi
process
cell
ingest
larg
particl
apoptot
cell
bacteria
particl
intern
vacuol
known
phagosom
correspond
author
minaosorio
p
pminaoso
nshsedu
function
viral
receptor
function
either
requir
result
intern
phenomenon
could
explain
function
trigger
antibodi
block
enzymat
activ
could
reduc
membran
level
therefor
aminopeptidas
activ
sever
molecul
known
associ
appear
regul
traffick
mechan
regul
function
potenti
import
endocytosi
regul
function
underscor
report
mutat
singl
site
polymorph
differ
splice
frequenc
human
gene
patient
hematolog
malign
mutat
lead
alter
traffick
could
pathophysiolog
implic
signal
transduct
propos
account
function
independ
enzymat
activ
howev
predict
short
cytoplasm
domain
contain
known
signal
motif
figur
box
reason
believ
signal
capac
depend
associ
auxiliari
protein
unknown
ident
sever
protein
recent
report
associ
reck
reversioninduc
cysteinerich
protein
kazal
motif
tumorassoci
antigen
might
constitut
auxiliari
molecul
contribut
signal
capabl
crosslink
monocyt
report
induc
mitogenactiv
protein
kinas
mapk
phosphoryl
ca
flux
cytokin
secret
cellular
adhes
coimmunoprecipit
adaptor
molecul
so
cell
dramat
increas
level
phosphoryl
syk
upon
cocrosslink
fcg
receptor
compar
crosslink
fcg
receptor
alon
found
suggest
function
regu
figur
function
three
mechan
action
human
shown
upon
ligand
bind
function
enzym
ii
receptor
andor
iii
signal
molecul
function
depend
least
one
mechan
action
list
b
name
peptid
cleavag
ii
endocytosi
iii
signal
transduct
mechan
result
biolog
phenomena
list
right
side
part
b
complex
phenomena
angiogenesi
invas
chemotaxi
must
occur
result
interplay
enzymat
activ
signal
function
similarli
upon
viru
mayb
even
cholesterol
ngrpeptid
bind
especi
ngrtarget
liposom
drug
receptor
function
could
mediat
signal
transduct
requir
endocytosi
function
interplay
mechan
action
repres
arrow
right
part
b
trend
molecular
medicin
lator
signal
trigger
receptor
belong
group
molecul
term
signal
regul
sr
common
observ
studi
signal
epitop
depend
signalinginduc
mab
find
could
explain
epitop
complex
report
exist
distinct
glycoform
also
although
substrat
incap
induc
signal
potenti
signal
induc
crosslink
p
minaosorio
unpublish
result
impli
enzymat
activ
becom
suscept
crosslink
ligand
possibl
open
constitut
close
conform
figur
box
follow
discuss
mainli
focu
function
membranebound
form
human
protein
refer
function
aspect
solubl
form
human
briefli
summar
box
cleav
nterminu
regul
activ
numer
peptid
particip
import
biolog
process
summar
tabl
one
best
known
function
role
viral
receptor
sever
speci
thu
receptor
human
coronaviru
porcin
respiratori
cov
porcin
transmiss
gastroenter
viru
tgev
felin
infecti
periton
viru
fipv
felin
enter
cov
fecov
canin
cov
ccov
region
amino
acid
identifi
essenti
infect
enzymat
activ
inhibitor
mutat
activ
site
affect
viru
bind
case
cov
serogroup
use
receptor
speciesspecif
manner
howev
felin
serv
receptor
group
cov
differ
glycosyl
differ
speci
constitut
one
import
determin
speci
specif
receptor
function
report
implic
viral
infect
human
cytomegaloviru
hcmv
mononuclear
cell
suscept
hcmv
infect
vitro
express
howev
antibodi
block
hcmv
infect
posit
cell
possibl
bind
molecul
virion
particip
earli
event
hcmv
infect
associ
hcmv
particl
matur
becom
immunogen
infect
consequ
autoantibodi
identifi
patient
activ
hcmv
infect
hcmvigg
posit
patient
inflammatori
bowel
diseas
ibd
strong
correl
express
enzymat
activ
invas
capac
numer
tumor
cell
type
valu
conform
chang
would
expos
catalyt
site
allow
entranc
substrat
process
could
explain
util
substrat
initi
recognit
site
exopeptidas
gxmen
motif
alreadi
propos
famili
member
monom
close
appos
allow
predict
rollov
mechan
occur
dynam
open
close
activ
site
propos
lendeckel
et
al
trend
molecular
medicin
prognost
indic
mani
type
neoplast
diseas
also
demonstr
among
neoplasia
report
overexpress
enzymat
activ
alter
skin
ovari
thyroid
lung
stomach
colon
kidney
bone
prostat
tumor
mechan
particip
tumorcel
invas
inevit
link
enzymat
activ
howev
invas
potenti
tumor
cell
also
block
mab
uncap
inhibit
enzymat
activ
signal
mechan
implic
role
cellular
differenti
deduc
least
three
type
observ
first
differenti
express
discret
state
differenti
normal
neoplast
myeloid
cell
phenomenon
account
wellrecogn
util
diagnost
marker
certain
type
leukemia
lymphoma
instanc
express
major
leukem
myeloblast
acut
myeloid
leukemia
although
express
lymphocyt
earliest
stage
differenti
becom
neg
cell
matur
second
express
regul
differenti
agent
phorbol
ester
transform
growth
factorb
tgfb
interleukin
il
final
chemic
inhibitor
bestatin
leuhistin
known
modul
cellular
differenti
vitro
although
specif
alway
demonstr
mani
case
blockad
bind
bestatin
antibodi
result
complet
abrog
effect
differenti
phenomenon
depend
induct
express
secret
growth
factor
cytokin
receptor
probabl
inhibit
enzymat
process
peptid
involv
regul
addit
recent
interest
studi
role
stemcel
differenti
promis
field
target
could
potenti
valu
capac
inhibitor
antibodi
suppress
prolifer
describ
mani
cell
type
exampl
inhibitor
bestatin
actinonin
mab
inhibit
enzymat
activ
report
suppress
growth
choriocarcinoma
leukemia
cell
line
cell
express
antisens
also
report
slower
growth
rate
cell
transfect
sens
sequenc
report
effect
bestatin
cell
prolifer
shown
effect
revers
human
promonocyt
cell
case
administr
bestatin
correl
upregul
membran
level
regard
also
report
high
level
correl
leukemiccel
resist
apoptosi
resist
overcom
treatment
bestatin
suggest
involv
enzymat
activ
howev
intracellular
concentr
bestatin
appear
import
effect
cell
prolifer
suggest
mechan
differ
inhibit
membranebound
furthermor
bestatin
appear
exert
effect
prolifer
even
cell
express
detect
level
therefor
work
necessari
clarifi
role
cell
prolifer
inhibitor
enzymat
activ
might
act
mechan
howev
effect
mab
report
regul
express
cellcyclerel
transcript
factor
support
direct
particip
process
regardless
mechan
clinic
use
chemic
inhibitor
might
hinder
effect
cell
prolifer
therefor
aspect
requir
investig
addit
recent
shown
bestatin
enhac
sensit
cervic
cancer
cell
radiat
underscor
box
structur
express
function
implic
heavili
glycosyl
kda
typeii
membran
protein
code
part
human
gene
anpep
locat
chromosom
express
renal
intestin
epithelia
nervou
system
synapt
membran
pericyt
myeloid
cell
monocyt
macrophag
dc
fibroblastlik
cell
synoviocyt
express
endotheli
cell
ec
also
report
although
other
claim
vivo
express
activ
angiogen
ec
contradictori
report
might
explain
sensit
detect
techniqu
use
immunohistochemistri
bind
peptid
presenc
discret
glycoform
conform
protein
might
recogn
certain
reagent
inde
via
substract
proteom
found
express
normal
rat
microvascular
ec
upregul
tumor
vessel
addit
sequenti
immunoprecipit
deglycosil
techniqu
five
differ
form
correspond
differ
oligosacharid
composit
found
ec
monocyt
structur
seven
domain
organ
classic
recogn
figur
threedimension
model
human
crystal
structur
apn
e
coli
publish
latter
four
domain
organ
describ
catalyt
domain
interact
domain
activ
site
insid
caviti
cover
ctermin
adomain
structur
might
share
sequenc
ident
low
membranebound
dimer
howev
epitop
map
studi
mutat
catalyt
site
well
similar
structur
metallopeptidas
famili
support
interact
domain
buri
activ
site
small
entranc
catalyt
site
would
explain
restrict
activ
short
peptid
figur
regard
conform
might
distinguish
tumor
normal
vasculatur
distinct
conform
depend
rel
posit
monom
mode
interact
report
rabbit
pig
dimer
membranebound
protein
conform
chang
associ
substrat
bind
might
correspond
chang
intermonomer
space
rather
intramolecular
conform
monom
mab
crosslink
might
trigger
signal
shorten
distanc
monom
oligomer
solubl
form
long
recogn
concentr
nm
human
serum
constitut
one
variou
ntermin
deriv
membranebound
counterpart
process
unknown
enzym
block
mabinduc
adhes
suggest
potenti
regulatori
role
membranebound
function
howev
fulli
activ
enzymat
thu
main
role
vivo
might
relat
cleavag
peptid
tumor
inflamm
site
repeatedli
report
upregul
trend
molecular
medicin
potenti
import
regul
prolifer
deathrel
phenomena
inhibitor
known
particip
tumor
cell
motil
spermatozoid
motil
first
case
mab
significantli
inhibit
migrat
cancer
cell
lung
cancer
cell
effect
correl
capac
mab
crosslink
stabl
express
membranebound
tumor
cell
incub
greatli
increas
migratori
capac
cell
express
enzymat
inact
mutant
also
show
increas
migrat
although
show
less
migrat
cell
express
enzymat
activ
form
sirna
highli
specif
chemic
inhibitor
block
migrat
endotheli
cell
ec
matrigel
motil
wound
heal
assay
mab
identifi
among
mab
rais
human
fibrosarcoma
cell
screen
inhibit
cell
motil
inhibit
motil
human
colon
carcinoma
human
lung
carcinoma
human
fibrosarcoma
cell
also
implic
spermatozoid
motil
account
total
protein
human
semin
plasma
highest
level
found
prostasom
membran
vesicl
enhanc
motil
ejacul
spermatozoa
role
motil
propos
catalyt
activ
semin
cytokin
enkephalin
known
play
role
sperm
motil
alter
male
infertil
addit
report
aminopeptidas
activ
sperm
correl
fertil
percentag
immobil
spermatozoa
neg
correl
activ
sperm
prostasom
correl
number
lymphocyt
aminopeptidas
activ
bronchoalveolar
fluid
patient
sarcoidosi
report
level
express
higher
alveolar
macrophag
patient
control
individu
purifi
induc
lymphocyt
chemotaxi
vitro
phenomenon
inhibit
bestatin
similarli
particip
lymphocyt
alveol
thorac
irradi
rat
well
lymphocyt
infiltr
synovi
fluid
patient
rheumatoid
arthriti
importantli
degrad
chemokin
downregul
modul
stromal
cellderiv
also
known
induc
migrat
addit
signal
trigger
crosslink
result
secret
suggest
enzymat
activ
mechan
involv
antigen
present
frequent
cite
antigenprocess
enzym
mainli
earli
studi
implic
extracellular
peptid
degrad
synthet
class
peptid
rest
state
enzymat
activ
site
cryptic
hidden
b
substrat
inhibitor
bind
initi
contact
site
induc
conform
chang
expos
cryptic
activ
site
well
cryptic
epitop
lie
close
result
activ
inhibit
enzymat
activ
conform
chang
might
also
involv
releas
galectin
consequ
concomit
unmask
carbohydr
moieti
involv
ligand
bind
could
explain
potenti
signal
function
substrat
upon
exposur
cryptic
epitop
autoantibodi
ligand
c
bind
crosslink
result
oligomer
signal
absenc
prebound
substrat
oligomer
multival
ligand
antibodi
virus
might
suffici
trigger
signal
intern
e
addit
substrat
antibodi
virusassoci
protein
regul
endocytosi
might
constitut
mechan
signal
inhibit
enzymat
activ
could
respons
dissoci
galectin
adaptor
molecul
would
explain
function
modul
mab
block
enzymat
activ
trend
molecular
medicin
dendrit
cell
dc
howev
direct
evid
involv
present
later
studi
support
role
extracellular
process
trim
antigen
peptid
protrud
mhc
class
ii
molecul
peptidas
inhibitor
antibodi
block
enzymat
activ
impair
antigen
present
intriguingli
antibodi
recogn
epitop
differ
catalyt
site
also
effect
capac
degrad
synthet
peptid
dc
thu
reduc
antigen
activ
also
shown
anoth
report
preincub
dc
three
differ
mab
result
inhibit
tcell
prolifer
least
one
mab
inhibit
enzymat
activ
suggest
either
differ
mechan
involv
enzymat
activ
modul
mabinduc
endocytosi
propos
figur
work
necessari
support
direct
role
antigen
present
isol
biliari
vesicl
patient
cholesterol
gallston
kda
protein
subsequ
identifi
shown
promot
cholesterol
crystal
vitro
later
identifi
major
concanavalinaassoci
protein
bile
concanavalinaassoci
protein
repres
major
sourc
cholesterol
crystal
agent
howev
use
similar
method
author
find
activ
suggest
protein
misidentifi
attribut
crystallizationpromot
activ
incorrect
nevertheless
protein
present
sera
patient
cholestat
diseas
later
found
high
molecular
isoform
kda
origin
liver
later
work
suggest
role
cholesterol
crystal
promot
vivo
crucial
develop
cholesterol
gallston
factor
thu
undermin
possibl
relev
pathogenesi
gallston
diseas
howev
diagnost
valu
still
undeni
function
cholesterol
uptak
stronger
experiment
support
report
target
ezetimib
merckscheringplough
pharmaceut
inhibitor
cholesterol
intestin
absorpt
although
anoth
protein
niemannpick
propos
main
target
drug
recent
report
ezetimib
equal
capabl
reduc
cholesterol
uptak
wildtyp
mice
bind
photoreact
ezetimib
kda
protein
enterocyt
membran
shown
suffici
effect
drug
purif
protein
identifi
inhibit
cholesterol
absorpt
bind
ezetimib
analog
affect
enzymat
activ
instead
propos
particip
endocytosi
cholesterol
enterocyt
bind
ezetimib
could
affect
associ
lipid
raft
induc
intern
ii
downregul
express
raftassoci
protein
implic
cholesterol
uptak
eg
fcg
receptor
andor
iii
interrupt
associ
fcg
receptor
induc
conform
chang
function
cooper
fc
receptor
report
link
role
cholesterol
uptak
fcg
receptor
function
propos
known
lipoprotein
regul
fcg
receptor
express
fcgreceptormedi
phagocytosi
thu
given
import
cholesterol
uptak
phagocyt
atherosclerosi
fact
ezetimib
block
lesser
degre
particip
metabol
enkephalin
hydrolys
ntermin
tyrgli
bond
leuenkephalin
metenkephalin
might
account
short
halflif
peptid
vivo
although
resist
hydrolysi
neuropeptid
substanc
p
inhibit
enkephalin
cleavag
angiotensin
hydrolyz
ntermin
arg
angiotensin
iii
gener
angiotensin
iv
normotens
hypertens
rat
infus
third
ventricl
caus
lower
blood
pressur
aminopeptidas
inhibitor
block
drop
blood
pressur
increas
vasopressin
releas
result
subsequ
increas
halflif
angiotensin
iii
dietari
salt
regul
express
kidney
highli
express
kidney
dahl
saltresist
rat
dahl
saltsensit
rat
reduc
basolater
na
k
atpas
level
via
angiotensin
iv
receptor
signal
tuftsin
first
peptid
bond
immunoregulatori
tetrapeptid
hydrolyz
gener
antagonist
compet
receptor
bind
thu
regul
tuftsin
function
kallidin
lysylbradykinin
deriv
lysdesarg
bradykinin
substrat
latter
gener
bradykinin
upon
hydrolisi
bradykinin
resist
hydrolysi
act
rather
natur
inhibitor
intriguingli
bradykinin
inhibitor
icatib
inhibitor
danger
possibl
crosstalk
system
bradykininreceptor
target
result
interf
inhibit
hemorphin
peptid
deriv
bchain
hemoglobin
share
ntermin
sequenc
angiotensin
iv
ie
vy
compet
catalyt
site
result
inhibitori
effect
activ
angiotensin
iv
vitro
hydrolyz
synthet
oligopeptid
correspond
n
terminu
although
natur
gcsf
resist
hydrolysi
believ
cleav
small
peptid
activ
cytokin
chemokin
would
requir
auxiliari
enzym
case
initi
remov
nh
termin
dipeptid
allow
truncat
extracellular
matrix
protein
high
molecular
weight
make
unlik
alon
capabl
degrad
nevertheless
least
two
protein
propos
cleav
entactin
nidogen
type
iv
collagen
due
potenti
relev
type
cleavag
tumor
cell
invas
assumpt
need
confirm
substrat
vitro
particip
metabol
glutathion
somatostatin
thymopentin
neurokinin
splenopentin
nociceptin
orphanin
fq
peptid
deriv
thrombin
receptor
trend
molecular
medicin
lowdens
lipoprotein
ldl
uptak
macrophag
determin
whether
target
ezetimib
cell
interest
question
current
address
report
activ
phagocyt
cell
monocyt
gate
peripher
blood
mononuclear
cell
express
twice
amount
less
phagocyt
cell
moreov
induct
differenti
cell
increas
phagocyt
capac
monocyt
diminish
express
cell
low
phagocyt
capac
high
phagocyt
capac
later
found
activ
particip
phagocytosi
spontan
redistribut
zone
phagocytetarget
interact
intern
phagosom
particl
simultan
crosslink
fcg
receptor
phagocytos
effici
particl
crosslink
fcg
receptor
alon
interestingli
particl
crosslink
alon
also
effici
phagocytos
although
satur
antibodi
concentr
necessari
rais
doubt
potenti
vivo
relev
phagocytosi
function
cooper
viral
receptor
fcg
receptor
import
implic
fc
receptor
particip
entri
mani
virus
via
antibodydepend
enhanc
infect
extracellular
peptidas
particip
angiogenesi
least
three
mechan
degrad
matrix
protein
ii
gener
peptid
angiogen
andor
antiangiogen
properti
iii
modul
signal
growth
andor
angiogen
factor
except
role
process
capillari
tube
format
marker
angiogen
vessel
extens
investig
studi
use
phage
display
technolog
identifi
tumorhom
peptid
result
discoveri
asparagineglycinearginin
ngr
peptid
resembl
integrinbind
peptid
arginineglycineaspart
acid
rgd
coupl
antitumor
drug
peptid
cngrc
cysasnglyargci
result
increas
efficaci
lower
toxic
rgd
peptid
bind
avintegrin
howev
peptid
compet
integrin
bind
phage
display
ngr
motif
suggest
exist
differ
receptor
ngr
sequenc
w
n
dgwl
identifi
peptid
mimic
bind
site
rgd
peptid
integrin
fact
sequenc
present
extracellular
domain
amino
acid
led
discoveri
function
receptor
ngr
tumor
blood
vessel
vessel
undergo
angiogenesi
sever
studi
demonstr
dramat
improv
capac
variou
drug
target
tumor
angiogen
vessel
vivo
coupl
ngr
ngrpeptid
liposom
one
potenti
caveat
use
ngr
peptid
fact
myeloid
cell
express
high
level
could
potenti
bind
ngr
howev
demonstr
ngrtumor
necrosi
factor
tnf
certain
antibodi
bind
exclus
express
tumor
express
normal
tissu
suggest
differ
isoform
express
tumor
underscor
potenti
ngr
peptid
tumor
target
other
shown
although
ngrtnf
cytolyt
activ
toward
myeloid
cell
line
activ
might
depend
bind
tnf
receptor
howev
dose
peptid
critic
thu
low
dose
drug
permit
effici
target
without
tnfreceptordepend
toxic
final
use
ngr
peptid
tool
detect
cardiac
angiogenesi
provid
evid
specif
ngr
peptid
angiogen
vasculatur
expand
use
diagnost
applic
group
report
hypoxia
angiogen
factor
induc
express
ec
enzymat
activ
inhibitor
impair
angiogenesi
vitro
howev
high
dose
bestatin
antibodi
requir
rais
concern
potenti
therapeut
use
tool
recent
public
address
concern
show
continu
treatment
therapeut
dose
bestatin
aminopeptidas
inhibitor
result
abrog
capillari
tube
format
suggest
effect
bestatin
specif
nevertheless
mani
studi
demonstr
capac
bestatin
antibodi
block
angiogenesi
vivo
well
potenti
prognost
signific
relat
angiogen
properti
type
cancer
final
mice
unequivoc
proven
import
molecul
angiogenesi
mice
dramat
decreas
retin
neovascular
hypox
condit
well
reduc
angiogen
respons
growth
factor
one
mechan
involv
appear
relat
associ
ec
propos
therapeut
target
tumor
origin
malign
endothelia
therefor
function
associ
underlin
import
antiangiogen
therapi
character
mab
observ
appear
diffus
express
cell
grow
independ
reloc
zone
cellcel
contact
confluenc
later
found
cellcel
contact
induc
express
lymphocyt
recent
found
crosslink
human
monocyt
result
strong
homotyp
aggreg
ha
phenomenon
signaltransductiondepend
independ
enzymat
activ
crosslink
result
polar
lead
edg
monocyt
migrat
toward
cell
form
aggreg
subsequ
accumul
zone
cellcel
contact
expand
work
found
constitut
associ
monocyt
dissoci
ha
ligat
n
terminu
result
complet
abrog
ha
addit
studi
role
review
trend
molecular
medicin
vol
adhes
monocyt
ec
found
monocyt
ec
complex
adhes
purifi
recombin
mediat
adhes
monocyt
importantli
induc
similar
effect
mab
block
viral
infect
experi
treat
mice
mab
periton
model
demonstr
impair
transendotheli
migrat
leukocyt
peritoneum
support
role
leukocyt
adhes
vivo
propos
ectoenzym
discuss
review
summar
figur
function
divid
three
group
accord
mechan
action
involv
enzymat
cleavag
peptid
endocytosi
signal
transduct
howev
one
mechan
like
requir
function
addit
evid
suggest
bind
substrat
autoantibodi
virus
induc
conform
chang
andor
cluster
trigger
signal
transduct
cascad
might
downregul
enzymat
activ
via
endocytosi
multifunction
respons
unexpect
clinic
complic
poor
efficaci
agent
especi
chemic
inhibitor
mislead
biolog
phenomena
vitro
modul
signalingdepend
function
enzymat
activ
inhibitori
compound
ii
undesir
modul
poorli
character
unknown
function
molecul
iii
differenti
modul
function
differ
tissu
iv
simultan
modul
differ
function
discret
tissu
v
requir
simultan
inhibit
auxiliari
enzym
obtain
signific
effect
vi
undesir
offtarget
effect
bind
discret
isoform
express
differ
cell
type
possibl
isoform
molecul
like
differenti
target
agent
character
exhaust
human
final
case
interplay
multipl
function
could
result
enhanc
therapeut
activ
certain
agent
instanc
induct
apoptosi
tumor
cell
target
ngr
peptid
coupl
chemotherapeut
drug
therefor
function
could
posit
neg
alter
outcom
therapeut
target
requir
investig
summari
major
characterist
drug
present
tabl
reason
specif
mab
use
along
chemic
inhibitor
studi
function
vitro
sever
mab
avail
known
block
viru
bind
recogn
isoform
express
tumor
discrimin
distinct
glycoform
compet
bind
natur
occur
autoantibodi
andor
trigger
signal
underlin
use
ligandmimick
tool
expand
list
autoimmun
diseas
autoantibodi
andor
high
level
aminopeptidas
activ
present
suggest
particip
pathogenesi
diseas
ibd
rheumatoid
arthriti
instanc
could
interest
model
test
efficaci
target
tool
especi
view
recent
report
antiinflammatori
effect
combin
blockad
vivo
time
appear
straightforward
predict
promis
approach
use
target
drug
tumor
vessel
instead
directli
modul
function
ngr
peptid
coupl
tnfa
melphalan
doxorubicin
interferona
endothelialmonocyteactiv
polypeptid
ii
alreadi
demonstr
improv
efficaci
vivo
howev
although
current
report
bind
discret
glycoform
protein
could
use
tissu
specif
target
design
recombin
antibodi
antibodi
clone
could
use
signal
modul
inhibit
viral
infect
promis
regard
low
antigen
peptid
specif
tumor
vessel
potenti
target
cell
type
myeloid
cell
complet
rule
new
insight
issu
hope
result
basic
research
clinic
trial
current
develop
understand
mechan
action
drug
major
goal
final
except
studi
regul
blood
pressur
nocicept
rodent
mani
function
discuss
observ
vitro
exclus
recent
anim
model
diseas
ibd
experiment
autoimmun
enceph
util
therefor
given
import
function
discuss
dramat
effect
manipul
vitro
next
challeng
translat
progress
field
take
studi
vivo
system
allow
better
understand
real
pathophysiolog
relev
well
ration
design
drug
two
critic
aspect
yet
studi
box
threedimension
structur
human
protein
express
profil
differ
glycoform
conform
protein
normal
diseas
human
tissu
